- Home
- LGI vs NVCT Comparison
LGI vs NVCT Comparison
Compare LGI & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGI | NVCT |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.3M | 220.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LGI | NVCT |
|---|---|---|
| Price | $17.99 | $9.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.33 |
| AVG Volume (30 Days) | ★ 64.9K | 48.5K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.95 | $5.55 |
| 52 Week High | $19.88 | $11.52 |
Technical Indicators
Market Signals| Indicator | LGI | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 34.58 | 54.34 |
| Support Level | $17.19 | $8.01 |
| Resistance Level | $19.30 | $9.20 |
| Average True Range (ATR) | 0.28 | 0.37 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 6.40 | 63.89 |
Price Performance
Historical ComparisonAbout LGI Lazard Global Total Return and Income Fund
Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.